Bayer Corp. and Janssen Pharmaceuticals Inc. seem to have the best defense against product liability suits claiming they did not provide adequate warning that Xarelto (rivaroxaban) increases the risk of bleeding: labeling that repeatedly specifies the risk.
In the fifth case to go to trial, Russell v. Janssen, jurors in a state court case in Philadelphia issued a verdict for the drug makers on April 27. The jury verdict form asked them: Do you find that the Xarelto warnings were inadequate
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?